Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial)

MLA

Sobha Sivaprasad, et al. “Is It Necessary to Use Three Mandatory Loading Doses When Commencing Therapy for Neovascular Age-Related Macular Degeneration Using Bevacizumab? (BeMOc Trial).” Eye, vol. 27, June 2013, pp. 959–63. EBSCOhost, https://doi.org/10.1038/eye.2013.93.

APA

Sobha Sivaprasad, Nirodhini Narendran, Yit C. Yang, R Chavan, Geeta Menon, & Manju Chandran. (2013). Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). Eye, 27, 959–963. https://doi.org/10.1038/eye.2013.93

Chicago

Sobha Sivaprasad, Nirodhini Narendran, Yit C. Yang, R Chavan, Geeta Menon, and Manju Chandran. 2013. “Is It Necessary to Use Three Mandatory Loading Doses When Commencing Therapy for Neovascular Age-Related Macular Degeneration Using Bevacizumab? (BeMOc Trial).” Eye 27 (June): 959–63. doi:10.1038/eye.2013.93.